Tornos Ascends To Zimmer Biomet CEO As Hanson Leaves For 3M Spinoff
Ivan Tornos will shift from COO to CEO of Zimmer Biomet now that former CEO Bryan Hanson has accepted the CEO job at 3M’s health care spinoff.
You may also be interested in...
This week, cardiac monitoring firm AngelMed announced its new name; Tempus nabbed FDA approval for its tumor profiling test; and iRhythm revealed that it’s been subpoenaed by the US Department of Justice.
The company’s health businesses include product lines worth nearly $9bn in annual sales. The deal is designed to allow both the new health care company and the “new 3M” to focus resources more efficiently on their separate priorities.
Zimmer Biomet’s net sales were up 1.2% year-over-year in the second quarter. CEO Bryan Hanson said the ROSA Knee robotic surgery system is performing even better than expected since it launched earlier this year, and is expected to be an important revenue-driver in the future.